– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – ...
- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; ...
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data ...
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical ...
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well ...
As of 8:26:17 a.m. GMT+1. Market Open. The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback